Millennium Management’s KalVista Pharmaceuticals KALV Stock Holding History

Millennium Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,500	Closed	-$380K	–	6045
2025 Q4	$380K	Buy	23,500 +3,500	+18%	+$46.4K	﹤0.01%	5119
2025 Q3	$244K	Buy	+20,000	New	+$276K	﹤0.01%	5451
2023 Q3	–	Sell	-50,000	Closed	-$450K	–	6345
2023 Q2	$450K	Buy	+50,000	New	+$461K	﹤0.01%	4614
2023 Q1	–	Sell	-100,000	Closed	-$676K	–	6608
2022 Q4	$676K	Buy	+100,000	New	+$536K	﹤0.01%	4508

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management's KALV Position: Q1 2026 in Review

Millennium Management reduced its KalVista Pharmaceuticals (KALV) stake by 34% in Q1 2026, selling an estimated $15.9M and leaving 1,912,146 shares worth $38.5M. The position accounts for 0.02% of the portfolio, ranked #1032.

Millennium Management first reported a position in KALV in Q2 2016 and has held it in 25 quarters since. The position peaked at $46.8M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Millennium Management held 1,912,146 shares of KalVista Pharmaceuticals worth $38.5M as of Q1 2026.
Millennium Management sold 984,520 KalVista Pharmaceuticals shares in Q1 2026, an estimated $15.9M.
KalVista Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1032 holding.
Millennium Management first reported a position in KalVista Pharmaceuticals in Q2 2016 and has held it in 25 quarters since.
Millennium Management's KalVista Pharmaceuticals position peaked at $46.8M in Q4 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.